SAVER: Supporting Adherence - Value-based Economic Resource

英国人口不断增长，老龄化不断加剧，导致对国民保健服务的需求不断增加。到2033/34年，医疗费用将达到国民收入的9.9%。我们迫切需要降低NHS的医疗成本。其他全球医疗保健市场也有降低医疗保健成本的强劲市场需求。例如，在美国，估计每年有12.5万人丧生，由于不遵守药物治疗，额外的医疗支出达到2900亿美元；此外，10%的老年患者住院治疗被认为可以通过改善服药依从性来避免。药物不依从性占治疗失败的50%，每年高达25%的住院治疗。研究表明，50-60%的慢性疾病患者在第一年错过剂量、服用错误剂量或放弃治疗。病人不能坚持服药的原因没有一个是不可克服的。由于患者依从性差造成的浪费成本目前是回顾性地衡量和报告的，而且是在人群水平上。然而，在现实中，这些成本是实时产生的，并且是由于个体临床医生和患者在制定和管理患者护理计划时做出的决定。Project SAVER是一项为期18个月的研究，由Inavya和Ipsos参与。该研究团队将开发一种经济工具来增强现有的Avatr技术，该技术将在临床医生和患者决策时测量和报告药物依从性的经济成本，为NHS和全球市场提供一个阶梯式的创新。

The UK population is increasing and getting older, causing ever-increasing demand on the NHS. By 2033/34, the cost will reach 9.9% of national income. There's a pressing need to reduce NHS healthcare costs.There's also strong market demand to reduce healthcare costs in other global healthcare markets. For example, in the US, an estimated 125,000 lives are lost annually and additional healthcare expenditures of $290 billion are driven by non-adherence to medication; and, 10% of hospitalisations in older patients are considered avoidable through improved medication adherence.Medication non-adherence accounts for 50% of treatment failures and up to 25% of hospitalisations each year. Studies show that 50-60% of patients with chronic illnesses miss doses, take the wrong doses, or drop off treatment in the first year. None of the reasons why patients are failing to adhere to medication are insurmountable.Wasted costs due to poor patient adherence are currently measured and reported retrospectively - and at population level. Yet, in reality, these costs accrue in real-time and are due to decisions made by individual clinicians and patients as they create and manage a patient's Care Plan.Project SAVER is an 18-month study with participation by Inavya and Ipsos. The research team will develop an economic tool enhancement to the existing Avatr technology, which will measure and report economic costs of medication adherence at the point of decision-making by clinicians and patients, delivering a step-change innovation for the NHS and global markets.